Trial Profile
A study to evaluate the effect of Golimumab Versus Tocilizumab in the treatment of Severe and Refractory Juvenile Idiopathic Arthritis (JIA)- uveitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Tocilizumab; Tocilizumab
- Indications Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism